Quiz: Incidence and Screening in Prostate Cancer

Article

How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.

In this quiz, you’ll get a chance to test your knowledge of incidence and screening in prostate cancer. Here’s your first question:

1.  Nearly half of U.S. prostate cancer deaths occur in men diagnosed after the age of ____.

A.74 years

B.76 years

C.78 years

D.80 years


12345>>>

 

 

Recent Videos
4 experts in this video
PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
4 experts in this video
The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Tanya B. Dorff, MD, on Results From Phase 1 CAR T-Cell Therapy mCRPC Trial
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Assessing the Benefit of CAR T-cell Therapies for mCRPC
Related Content
Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer

Roman Fabbricatore
March 24th 2025
Article

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

New Partnership May Expand Use of Prostate Cancer AI Technology Platform

Russ Conroy
February 27th 2025
Article

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.